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Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concentrations, lipid
metabolism, gut motility, appetite and body weight, and immune function, providing a scientific basis for
utilizing incretin-based therapies in the treatment of type 2 diabetes. Activation of GLP-1 and GIP receptors
also leads to nonglycemic effects in multiple tissues, through direct actions on tissues expressing incretin
receptors and indirect mechanisms mediated through neuronal and endocrine pathways. Here we contrast
the pharmacology and physiology of incretin hormones and review recent advances in mechanisms coupling
incretin receptor signaling to pleiotropic metabolic actions in preclinical studies. We discuss whether
mechanisms identified in preclinical studies have potential translational relevance for the treatment of human
disease and highlight controversies and uncertainties in incretin biology that require resolution in future
studies.Introduction to Incretin Biology
Incretins are gut hormones that potentiate insulin secretion after
meal ingestion in a glucose-dependent manner. The two best-
studied incretins, glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1), exert their insulino-
tropic actions through distinct G-protein-coupled receptors
highly expressed on islet b cells. The GLP-1 and GIP receptors
are also widely expressed in nonislet cells (Figure 1) and also
exert indirect metabolic actions (Figure 2); hence, there is
considerable interest in identifying extrapancreatic actions of in-
cretin hormones. Two strategies encompassing potentiation of
incretin receptor signaling have been pursued for the treatment
of type 2 diabetes. Inhibition of dipeptidyl peptidase-4 (DPP-4),
the enzyme responsible for N-terminal cleavage and inactivation
of GIP and GLP-1, has been achieved through the use of orally
available medications with high selectivity for the catalytic sub-
unit of DPP-4. A second class of incretin-based therapies is
comprised of injectable GLP-1R agonists that exhibit structural
homology to human GLP-1 or to nonmammalian GLP-1R ago-
nists. The insulinotropic properties of GIP and GLP-1 were iden-
tified more than 25 years ago; however, new actions of incretin
hormones continue to be identified. We now discuss recent
advances in our understanding of incretin hormone action since
the last review in this journal (Drucker, 2006). Wherever
possible, we contrast mechanisms and actions deduced from
pharmacological (Figures 1 and 2) and physiological (Figure 3)
preclinical experiments, with comparable data from human
studies. As incretin action in the cardiovascular system has
recently been reviewed elsewhere (Ussher and Drucker, 2012),
we focus our review on noncardiovascular actions of GLP-1
and GIP.
Synthesis and Secretion of Incretins
GLP-1
GLP-1 is synthesized in and secreted from enteroendocrine L
cells found throughout the small and large intestine, after post-
translational processing of proglucagon by prohormone conver-tase 1/3 (PC1/3). Original concepts of L cells as predominantly
unihormonal or bihormonal have evolved to reflect evidence
that enteroendocrine L cells exhibit a molecular profile overlap-
ping with other gut endocrine cell types and coexpress multiple
peptide hormones, with diversity of peptide hormone coexpres-
sion changing along the length of the gastrointestinal tract (Habib
et al., 2012). Localized GLP-1:GLP-1R expression in rodent
circumvallate papillae and adjacent salivary glands has been
described andGlp1r/mice exhibit altered responses to sweet-
eners in behavioral assays (Shin et al., 2008). GLP-1 is also pro-
duced in the central nervous system (CNS), predominantly in the
brainstem, from where it transported throughout the brain to
elicit metabolic, cardiovascular, and neuroprotective actions
(discussed below). Furthermore, coexpression of GLP-1 and
PC1/3 has been identified in a subset of rodent and human a
cells via immunohistochemistry and mass spectrometry,
although the functional significance and extent of a cell GLP-1
production in normal uninjured islets remains uncertain (Marche-
tti et al., 2012). GLP-1 production in rodent and human a cells is
induced by interleukin-6 (IL-6), as exemplified by exercise or
exogenous administration of IL-6 (Ellingsgaard et al., 2011).
The constant basal secretion of GLP-1 from enteroendocrine
cells is rapidly augmented by the ingestion of luminal nutrients,
including carbohydrates, fats, and proteins (Diakogiannaki
et al., 2012). The relative importance of (1) hormones, (2) neural
signals, (3) luminal nutrient interactions with enterocytes and
gut endocrine cells, and (4) active nutrient absorption for the con-
trol of GLP-1 secretion is uncertain (Reimann et al., 2012).
Although metformin rapidly enhances GLP-1 but not GIP secre-
tion from rodent and human L cells (Maida et al., 2011; Migoya
et al., 2010), the actions of metformin to stimulate intestinal
GLP-1 secretion are indirect and incompletely understood.
Levels of GLP-1 in lymph are higher than corresponding levels
in portal venous plasma and secretion of GLP-1 is partially
dependent upon intestinal chylomicron secretion as deduced
in studies using surfactant to inhibit enteral lipid-stimulated
chylomicron formation in rats (Lu et al., 2012).Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 819
Figure 1. Direct Pharmacological Actions of GLP-1R Agonists
GLP-1R agonists act directly via the GLP-1R on pancreatic islets, heart, intestine, subpopulations of immune cells, kidney, and brain.
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GIP is a 42 amino acid peptide synthesized in and secreted from
enteroendocrine K cells located primarily in the duodenum and
proximal jejunum, and CNS production of GIP has also been
described. GIP messenger RNA (mRNA) and protein have
been localized to the a cell in mouse and human islets; however,
the prohormone is processed by PC2 (rather than PC1/3 as
seen in the K cell) to yield a 30 amino acid protein (GIP1–30) (Fu-
jita et al., 2010). GIP1–30 increases insulin secretion in perfused
mouse pancreata, and immunoneutralization of GIP decreased
glucose-stimulated insulin secretion in isolated mouse islets,
consistent with the local release of an insulinotropic GIP peptide
from a cells (Fujita et al., 2010). Ectopic expression of biologi-
cally active GIP has also been localized to b cells in mice with
targeted inactivation of the Gcg gene (Fukami et al., 2013).
The physiological importance of local GIP production in islets
under different conditions is difficult to ascertain, and awaits
studies of mice with targeted inactivation of the GIP gene in a
and/or b cells. Although the molecular control of GIP biosyn-
thesis in gut K cells is poorly understood, analysis of gene
expression in isolated K cells identified regulatory factor X 6
(Rfx6) as an important determinant of GIP biosynthesis and
secretion from K cells (Suzuki et al., 2013) and increased Rfx6
expression in K cells correlates with increased GIP secretion
in high-fat-fed mice.820 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.Biological Actions of Incretins
Pancreas
GLP-1 increases insulin and inhibits glucagon secretion in
a glucose-dependent manner (Drucker, 2006). GLP-1 also
increases insulin synthesis, confers glucose sensitivity to
glucose-resistant b cells, stimulates b cell proliferation and neo-
genesis, and inhibits b cell apoptosis. The mechanisms through
which GLP-1 inhibits glucagon secretion from a cells are contro-
versial. Although a small subset of a cells express the GLP-1R,
GLP-1 may inhibit glucagon secretion through one or more
b-cell-derived products, such as insulin, GABA, or zinc. Never-
theless, GLP-1R agonists robustly inhibit glucagon secretion in
C-peptide-negative subjects with T1DM (Dupre´ et al., 2004),
illustrating that the b cell is not essential for transducing the
glucagonostatic actions of GLP-1. Evidence from experiments
employing somatostatin receptor 2 (SSRT2) antagonists and
Ssrt2/ mice strongly suggests that the inhibitory actions of
GLP-1 on a cells are indirect and mediated through somato-
statin-dependent mechanisms (de Heer et al., 2008).
GLP-1R Signaling in the b Cell. TCF7L2, a transcription factor
activated by the Wnt/b-catenin pathway, plays a central role in b
cell physiology, and gene variations of Tcf7l2 are the strongest
known genetic risks factors for b cell dysfunction and T2DM
(Grant et al., 2006). Exendin-4 (Ex-4; 2 nM) stimulated canonical
Wnt signaling in INS-1 cells and isolated mouse islets, actions
Figure 2. Indirect Pharmacological Effects of GLP-1R Agonists
Activation of GLP-1R signaling pathways in the brain leads to biological actions in the liver, adipose, and gastrointestinal tract.
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GLP-1R stimulation increased the phosphorylation and stabiliza-
tion of b-catenin, through a cAMP/PKA mechanism sensitive to
AKT and ERK1/2 inhibition, and enhanced b-catenin/TCF7L2-
mediated transcription of cyclin D1 mRNA, leading to increased
b cell proliferation (Figure 4); the GLP-1R-dependent stimulation
of b cell proliferation was abolished by small interfering RNA
(siRNA) targeting b-catenin or after transfection of a dominant-
negative TCF7L2 retrovirus in INS-1 cells (Liu and Habener,
2008). Notably, levels of Wnt-4 RNA and protein are robustly
increased by Ex-4 in murine islets and INS-1 cells, and knock-
down of Wnt-4 attenuated the GLP-1R-dependent stimulation
of cell proliferation (Heller et al., 2011). Similarly, basal TCF7L2
and incretin receptor expression assessed by immunohisto-
chemistry was reduced in islets from diabetic human pancreas.
Knockdown of Tcf7l2 mRNA transcripts decreased levels of
Glp1r mRNA and immunoreactive GLP-1R protein in human is-
lets from nondiabetic subjects and abrogated the GLP-1-depen-
dent (100 nM) potentiation of insulin secretion in perifusion
experiments (Shu et al., 2009). Consistent with these findings,
mice with pancreas-specific deletion of Tcf7l2 exhibit impaired
b cell function, reduced islet Glp1r expression, and defective
GLP-1-stimulated insulin release from isolated islets (da Silva
Xavier et al., 2012). Murine islets deficient in chicken ovalbumin
upstream promoter transcription factor II (COUP-TFII) expres-
sion also exhibit reduced levels of Glp1r and Pdx1 mRNA tran-scripts, decreased b cell mass, and defective GLP-1R-depen-
dent induction of b-catenin and target genes such as cyclin D1
and axin 2 (Boutant et al., 2012). Hence, the TCF7L2/Wnt
pathway represents an important target for GLP-1 action in
b cells.
Human nondiabetic subjects with SNPs in the Tcf7l2 gene (TT
or TC at rs7903146) exhibit reduced insulin secretion in response
to oral but not intravenous glucose, with no differences in circu-
lating GLP-1 or GIP levels or insulin sensitivity, consistent with
the notion that reduction in TCF7L2 impairs b cell incretin
responsivity (Villareal et al., 2010). Nondiabetic carriers of the
diabetes-associated Tcf7l2 variant allele exhibit normal b cell
function in response to exogenous GLP-1 infusion during a hy-
perglycemic clamp (Smushkin et al., 2012). In contrast, insulin
secretion in response to oral glucose or a mixed meal was
reduced in nondiabetic carriers of rs7903146 or rs12255372,
and the insulinotropic response to exogenous GLP-1 and GIP
was impaired during a hyperglycaemic clamp (Pilgaard et al.,
2009; Scha¨fer et al., 2007). Although TCF/Wnt signaling was
implicated in the control of intestinal proglucagon gene expres-
sion (Yi et al., 2005), the available evidence indicates that Tcf7l2
risk variants are associated with normal GLP-1 secretion but
impaired GLP-1 action in human subjects.
b-arrestin-1 is required for GLP-1R signaling in the b cell
(Figure 4). b-arrestin-1 associates with the GLP-1R in INS-1 cells
exposed to GLP-1 (100 nM for 3–10 min) (Sonoda et al., 2008).Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 821
Figure 3. Physiological Roles of Endogenous GLP-1
The biological actions of GLP-1 as revealed by loss-of-function studies utilizing Glp1r/ mice or antagonists of the GLP-1R are shown and summarized in the
accompanying table.
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lated (100 nM) cAMP production and induction of IRS2 and
decreased CREB and ERK1/2 phosphorylation, severely blunt-
ing the ability of GLP-1 to augment glucose-stimulated insulin
secretion in INS-1 cells. Although b-arrestin-1 controls mem-
brane receptor internalization and desensitization, knockdown
of b-arrestin-1 had no effect on GLP-1R surface expression
(Sonoda et al., 2008). b-arrestin-1 is also required for the GLP-
1-mediated stimulation of the second wave of biphasic ERK1/2
phosphorylation (Quoyer et al., 2010). GLP-1R activation pro-
moted b-arrestin-1 association with ERK1/2, leading to sus-
tained activation and sequestration of phosphorylated ERK1/2
in the cytoplasm (Quoyer et al., 2010). Maintenance of cyto-
plasmic levels of phosphorylated ERK1/2 activated p90 ribo-
somal S6 kinase (p90RSK) and led to the phosphorylation and
inactivation of BAD (Bcl-xL/Bcl-2-associated death promoter
homolog), linking GLP-1R signaling to enhanced cell survival
(Quoyer et al., 2010). GLP-1 failed to prevent apoptosis or stim-
ulate insulin secretion in MIN-6 cells treated with b-arrestin-1
siRNA or in islets from b-arrestin-1/ mice (Quoyer et al.,
2010). Hence, b-arrestin-1 is required for GLP-1R-dependent
enhancement of insulin secretion and b cell cytoprotection.
Insulin-like growth factor (IGF) signaling also regulates the bio-
logical actions of GLP-1 in the b cell (Figure 4). GLP-1 (100 nM,
18 hr) increased the expression of IGF-1R protein, but not822 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.mRNA, in MIN-6 cells and mouse islets (Cornu et al., 2010),
actions mediated through cAMP- and PKA-dependent mecha-
nisms. Knockdown of IGF-1R prevented the GLP-1 induction
of Akt and BAD phosphorylation and blunted the antiapoptotic
actions of GLP-1 in cytokine-treated MIN-6 cells and mouse
islets. The ability of GLP-1 to phosphorylate Akt correlated
with the glucose-stimulated release of IGF-2, as both diazoxide
(200 uM) and nimodipine (1 uM) reducedGLP-1-mediated secre-
tion of IGF-2 and blocked Akt phosphorylation (Cornu et al.,
2009). Furthermore, reduction of IGF-2 action by RNA silencing
or blocking antisera rendered MIN-6 cells and mouse islets
insensitive to GLP-1-mediated reduction in cytokine-induced
apoptosis (Cornu et al., 2009). GLP-1 stimulation of the IGF-
1R/IGF-2 pathway enhances b cell proliferation, whereas
GLP-1 (100 nM, 48 hr) failed to increase b cell proliferation in
Igf1r/ mouse islets and in islets treated with either IGF2 short
hairpin RNA or antisera (Cornu et al., 2010). Thus, GLP-1R
signaling promotes cell survival by increasing the release of
IGF-2 and stimulation of an IGF-1R/IGF-2 autocrine loop.
Identification of a Gut-Brain GLP-1 Axis. GLP-1 stimulates in-
sulin secretion and regulates glucose concentrations through
both pancreatic and extrapancreatic mechanisms (Figure 3).
The hepatoportal region is exposed to higher concentrations
of active GLP-1 compared to the systemic circulation and
activation of hepatoportal glucose sensor(s) increases glucose
Figure 4. GLP-1 Signal Transduction Pathways in the Pancreatic b Cell
Recent studies delineating roles for b-arrestin-1, b-catenin, and IGF-1R signaling in the effects of GLP-1 on insulin secretion, b cell growth, and function are
illustrated.
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insufficient to increase systemic glucose concentrations differ-
entially regulates c-Fos expression in neuronal subpopulations
and increasedmuscle glycogen synthesis; these actions of intra-
gastric glucose were diminished after central infusion of Ex-9
and were absent in Glp1r/mice. Furthermore, the ability of in-
tragastric glucose to activate Fos expression in the CNS in a
GLP-1R-dependent manner was markedly diminished in high-
fat-fed insulin-resistant mice (Knauf et al., 2008b).
Glp1rmRNA transcripts have been identified in the rat nodose
ganglion, which contains vagal afferent nerves, and an immuno-
reactive GLP-1R protein was detected by western blotting and
immunohistochemistry in the portal vein (Vahl et al., 2007). The
importance of the portal GLP-1R is revealed by data showing
that low dose intraportal but not intrajugular systemic infusion
of the GLP-1R antagonist [des-His(1),Glu(9)] exendin-4 impaired
glucose tolerance. Portal infusion of glucose led to substantially
greater glucose clearance relative to the same amount of
glucose administered via the femoral vein in mice, and attenua-
tion of portal GLP-1R signaling with Ex-9 (0.5 pmol/kg/min) pre-
vented activation of the hepatoportal glucose sensor (Burcelin
et al., 2001). Similarly, portal infusion of glucose into Glp1r/
mice failed to preferentially activate glucose clearance. Local
potentiation of incretin action through selective inhibition of in-
testinal but not systemic DPP-4 activity is also sufficient toenhance glucose tolerance, independent of changes in plasma
GIP, GLP-1, or insulin, in association with enhanced vagal nerve
discharge (Waget et al., 2011). Hence, enteral nutrients activate
a functional GLP-1R in the portal vein, initiating a vagal reflex cir-
cuit to control whole-body glucose disposal, independent of in-
creases in insulin secretion. Whether this mechanism is similarly
important for enteral glucose disposal in humans is difficult to
ascertain.
A role for CNS GLP-1R signaling in the control of glucose
homeostasis has been proposed. Intracerebroventricular (i.c.v.)
Ex-4 (0.5 pmol/kg/min) increased plasma insulin levels during a
hyperglycaemic clamp in wild-type (WT) but not in Glp1r/
mice, whereas i.c.v. Ex-9 increased muscle glucose utilization
independent of muscle insulin action though mechanisms
requiring intact vagal innervation (Knauf et al., 2005). Similarly,
Glp1r/ mice exhibited increased glucose disappearance,
enhanced glucose disposal in muscle, and increased muscle
glycogen levels during insulin clamps and fail to regulate glucose
appropriately during acute exercise (Ayala et al., 2009). Never-
theless, the hyperglycemia arising in Glp1r/ mice during
exercise was due to impaired suppression of hepatic glucose
production and not to defective muscle glucose uptake. Ex-4
infused into the brain for 3 hr decreased whole-body glucose
utilization in the awake, free-moving mouse clamped under
hyperinsulinemic-hyperglycemic conditions, in association withCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 823
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actions of CNSGLP-1R signalingwere blocked by coadministra-
tion of Ex-9 and eliminated in Glp1r/ mice. Furthermore,
chronic i.c.v. administration of Ex-9 blocked the development
of hyperinsulinemia and insulin resistance in high-fat-fed mice,
independent of changes in food intake or body weight, consis-
tent with development of increased energy expenditure pursuant
to reduction in brain GLP-1R signaling (Knauf et al., 2008a).
These observations are concordant with the phenotypes of
resistance to diet-induced obesity, increased activity, and
enhanced energy expenditure in high-fat-fed Glp1r/ mice
(Hansotia et al., 2007). The central GLP-1R-dependent reduction
of femoral blood flow was associated with reduced hypothalam-
ic reactive oxygen species (ROS) and increased vagus nerve
activity; provision of ROS donor reversed the effect of brain
GLP-1 signaling on peripheral blood flow (Cabou et al., 2008).
Under conditions of a hyperglycemic-hyperinsulinemic clamp,
central Ex-4 not only reduced femoral blood flow, but also
impaired peripheral insulin sensitivity, actions associated with
enhanced hypothalamic membrane protein kinase C-d (PKC)
translocation. Conversely, under the same conditions, femoral
blood flow and insulin sensitivity were enhanced in Glp1r/
mice or in WTmice with brain infusion of Ex-9. The central action
of Ex-4 on blood flow and insulin sensitivity were mimicked by
phorbol-12-myristate-13-acetate (PMA) and blocked by cal-
phostin C, a nonspecific PKC inhibitor, as well as rottlerin, a
selective PKC-d antagonist (Cabou et al., 2011). Furthermore,
hypothalamic PKC-d activity was increased in high-fat-fed dia-
betic WT mice, and intrahypothalamic rottlerin enhanced both
femoral artery blood flow and insulin sensitivity.
The available evidence suggests that enteric glucose absorp-
tion activates GLP-1R-sensitive CNS networks that promote
enhanced glucose disposal. Whether GLP-1R-dependent CNS
pathways are similarly activated by other nonglucose macronu-
trients remains uncertain; however, fructose attenuates the
anorectic actions of exendin-4 in the CNS via an AMPK-de-
pending pathway (Burmeister et al., 2013), evidence for cross-
talk in nutrient sensing GLP-1R-dependent pathways controlling
food intake. Furthermore, brain GLP-1R signaling controls
peripheral blood flow and insulin sensitivity predominantly under
hyperinsulinemic, hyperglycemic conditions. The relative impor-
tance of central versus peripheral GLP-1 action for control of
glucose homeostasis remains uncertain as transgenic rescue
of GLP-1R expression in pancreatic ductal and b cells under
the control of the Pdx-1 promoter normalized glucose intoler-
ance in nondiabetic Glp1r/ mice and completely restored
the insulinotropic and b cell proliferative effects of exogenous
Ex-4 (Lamont et al., 2012). Unexpectedly however, transgenic
mice with selective b cell rescue of the human GLP-1R did not
exhibit impaired glucose tolerance after peripheral administra-
tion of the GLP-1R antagonist Ex-9. Hence, these findings,
together with studies of GLP-1 action in the brain, emphasize
the importance of both the b cell GLP-1R and neural-GLP-1R-
dependent communication, as key contributors to GLP-1R-
dependent regulation of glucose homeostasis. Whether the
CNS GLP-1R system is similarly important for control of blood
flow or glucoregulation in humans awaits the development of
CNS penetrant versus nonpenetrant GLP-1R agonists suitable
for use in human subjects.824 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.GLP-1 Actions Promoting Cell Growth. GLP-1 rapidly stimu-
lates b cell proliferation and engages proliferative and antiapop-
totic pathways in the rodent b cell, resulting in expansion of b cell
mass in preclinical studies (Drucker, 2003). Furthermore, GLP-
1R signaling enhances b cell survival in human islets in vitro
and in islet transplant studies of rodent and human islets in
animals in vivo (King et al., 2005). These observations have
prompted investigation of GLP-1R agonists as adjuvant therapy
in human subjects receiving islet cell transplants. However,
compelling evidence for benefit of GLP-1R agonists in these
patients remains elusive. Although exenatide improved glycemia
and enhanced b cell function in some islet graft recipients
(Faradji et al., 2008), the human studies to date are small, non-
randomized, and of short duration. Furthermore, GLP-1R ago-
nists are poorly tolerated in many subjects with T1DM and islet
transplants, and native GLP-1 failed to suppress glucagon
secretion from islets transplanted into human recipients (Rickels
et al., 2009). Notably, the proliferative actions of GLP-1R ago-
nists are markedly attenuated or absent in older rodents, likely
reflecting epigenetic alterations in the capacity for b cell mitosis,
downregulation of p27, and increased expression of 16Ink4a, a
negative regulator of cyclin dependent kinase 4 (Rankin and
Kushner, 2009; Tschen et al., 2009, 2011). Similarly, the capacity
for human islets from older donors to exhibit a proliferative
response to GLP-1R agonists remains unclear and appears to
be limited (Tian et al., 2011).
Ex-4 also induced expansion of pancreatic ductal glands in the
rat pancreas, and 12 weeks of Ex-4 administration increased
pancreas weight, in association with histological findings of
chronic pancreatitis in mice with pancreatic-specific expression
of the oncogene Kras (Gier et al., 2012). In contrast, GLP-1R acti-
vation inhibited cell growth and augmented apoptosis in murine
CT26 colon cancer cells that express an endogenous functional
GLP-1R (Koehler et al., 2011), highlighting that the growth-
modulating properties of GLP-1R signaling are highly cell spe-
cific. Sustained GLP-1R activation also increased the mass of
the mucosal epithelium in the rodent small bowel and, to a lesser
effect, in the colon through incompletely defined mechanisms
(Simonsen et al., 2007). GLP-1R expression has been identified
in rodent thyroid C cells; acute GLP-1R activation increases
calcitonin levels in rodents and sustained activation of GLP-1R
signaling produces C cell hyperplasia andmedullary thyroid can-
cer in rodents, to a greater extent in rats than mice (Bjerre Knud-
sen et al., 2010). The proliferative actions of GLP-1R agonists
were not associated with RET orMAP kinase activation inmurine
C cells. However C cell GLP-1R density and proliferation in
response to GLP-1R agonists is highly species specific, and
GLP-1R agonists do not promote C cell proliferation or increases
in calcitonin levels in primate studies after 87 weeks of exposure
(Bjerre Knudsen et al., 2010). Furthermore, the available clinical
data from studies of diabetic or nondiabetic obese subjects
receiving continuous treatment with liraglutide for up to 2 years
do not reveal significant increases in calcitonin levels over
time (Hegedu¨s et al., 2011). Nevertheless, the engagement of
proliferative signaling pathways in multiple tissues after adminis-
tration of GLP-1R agonists suggests that ongoing scrutiny and
monitoring of patients treated for prolonged periods of time
with GLP-1R agonists for the possible development of malig-
nancy is appropriate. The low incidence of pancreatic cancer
Cell Metabolism
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cancer (less than 1:100,000) in human subjects suggests that
even meta-analyses of ongoing randomized controlled clinical
trials of diabetic subjects treated with GLP-1R agonists to
assess cardiovascular safety (Ussher and Drucker, 2012) will
be insufficiently powered to clarify any potential relationship
between incretin-based therapies and cancer incidence.
GLP-1 Action on b Cell Function and Glycemic Control in
Humans. GLP-1 induces glucose competence in nonresponsive
b cells ex vivo (Holz et al., 1993) and enhances and/or restores
glucose sensing and sulfonylurea sensitivity to diabetic human
b cells in vivo (Gutniak et al., 1996), through poorly understood
mechanisms. Conversely, the strict glucose-dependence of
GLP-1 action on the human b cell is abrogated by concomitant
administration of sulfonylureas (de Heer and Holst, 2007). The
robust stimulation of b cell proliferation in rodents coupled
with cytoprotective actions of GLP-1R signaling in rodent and
human islets fostered considerable interest in whether incretin-
based therapies might exert durable actions in subjects with
T2DM. Although 2 years of treatment with the GLP-1R agonist
liraglutide produced significantly greater reductions in HbA1c
relative to the active comparator glimepiride in subjects with
T2DM, only 43% of the originally randomized population
completed the 2 year trial (Garber et al., 2011). Furthermore,
while a substantial subset of liraglutide-treated patients main-
tained good glycemic control over the 2 year treatment period,
a considerable proportion, 20% of patients failed to maintain
glycemic control on liraglutide (Garber et al., 2011). Similarly,
while more diabetic patients treated with twice daily exenatide
maintained adequate glycemic control relative to subjects
treated with glimepiride in an open label study, only 138 out of
the initial 515 patients randomized to exenatide completed the
study, and 39% of exenatide-treated patients failed to maintain
adequate glycemic control (Gallwitz et al., 2012). Bunck and col-
leagues compared b cell function using sequential glucose
clamp studies in a small number of subjects randomized to inten-
sive therapy with exenatide at higher than clinically approved
doses, versus insulin glargine, for 3 years. No meaningful differ-
enceswere seen in HbA1c ormultiple measures of b cell function
across different treatment groups (Bunck et al., 2011). Although
exenatide-treated subjects exhibited an increased disposition
index 4 weeks after cessation of therapy, whether this difference
reflects a beneficial direct effect of exenatide on b cell function or
simply the indirect benefit of a substantial 7.9 kg weight loss in
subjects receiving exenatide cannot be determined (Bunck
et al., 2011). Hence, these and other clinical studies do not sup-
port the concept that treatment with GLP-1R agonists improves
functional b cell mass over time in human diabetic subjects.
GIP Action in the Pancreas. GIPR activation in the b cell in-
creases insulin secretion through cAMP/PKA and cAMP/Epac2
pathways, whereas Gipr/ mice exhibit impaired oral but
normal intraperitoneal glucose tolerance, consistent with the
known incretin action of GIP (Miyawaki et al., 1999). The mech-
anisms mediating defective GIP responsivity in experimental
and clinical diabetes involve downregulation of GIP receptor
expression and/or attenuation of receptor signaling. Partial
pancreatectomy resulted in hyperglycemia and reduced islet
Gipr and Glp1r mRNA and protein expression in rats after
4 weeks, which was prevented by reducing hyperglycemia withphlorizin (Xu et al., 2007). The b cellGipr is transcriptionally upre-
gulated by PPAR-g, and Gipr mRNA transcripts are reduced in
islets from Pparg/ mice, potentially linking glucotoxicity to
reduced PPAR-g activity and decreased Gipr expression (Gupta
et al., 2010). Loss of GIP responsivity and Gipr expression was
associated with ubiquitination and GIP receptor degradation
under conditions of hyperglycemia in rodent and human islets.
In contrast, theGlp1r, but not theGipr, appears to be downregu-
lated by nonesterified fatty acids in rodent islets. Although
exogenous GIP fails to stimulate insulin secretion in most hyper-
glycemic subjects with T2DM, a 4 week course of insulin therapy
improved glycemic control (HbA1c of 7%) and restored the in-
sulinotropic response to exogenous GIP in human diabetics
(Højberg et al., 2009). The resistance to GIP action in diabetic
subjects is not restored by acute coadministration of xenin-25,
a neurotensin-related peptide that potentiates the insulinotropic
actions of GIP in nondiabetic subjects (Wice et al., 2012). Human
subjects with a SNP (rs10423928) in the Gipr gene exhibit
reduced islet Gipr mRNA transcripts, secrete less insulin in
response to exogenous GIP (240 pmol/kg/hr), and display
impaired incretin responses and elevated 2 hr glucose levels dur-
ing an OGTT (Lyssenko et al., 2011; Saxena et al., 2010). Hence,
genetic and adaptive changes inGipr expression may contribute
to the pathophysiology of the impaired incretin response in sus-
ceptible individuals.
GIP exhibits antiapoptotic actions (Figure 5) in INS-1 cells and
isolated mouse islets in association with phosphorylation of AKT
(Ser473), inhibition of apoptosis signal regulating kinase-1 acti-
vation, and enhanced EPAC2 signaling independent of PI3K or
PKA activation (Widenmaier et al., 2009). GIP (100 nM) increased
the expression of the antiapoptotic protein Bcl-2 in INS-1 cells
through PKA-dependent phosphorylation of CREB. Although
D-[ALA2]GIP (24 nM/kg) administration reduced levels of cleaved
caspase-3 in islets of STZ-treated mice, Gipr/ mice did not
exhibit enhanced susceptibility to STZ-induced b cell apoptosis
(Maida et al., 2009). The differential sensitivity ofGlp1r/ but not
Gipr/ b cells to apoptotic injury may be explained by coupling
of basal GLP-1R (but not GIPR) signaling to genes and proteins
essential for b cell survival (Maida et al., 2009).
GIP receptors have been localized to rodent and human a cells
and GIP infusion (20 ng/kg/min) increased plasma levels of
glucagon and enhanced glucose excursion during a meal test
in subjects with T2DM (Chia et al., 2009). Whether GIPR activa-
tion can provide further glucoregulatory benefit on top of
treatment with GLP-1R agonists is uncertain. Transient GIP
(4 pmol/kg/min) infusion failed to significantly augment the insu-
linotropic effects of GLP-1 (1.2 pmol/kg/min) and reversed the
glucagonostatic action of GLP-1 (Mentis et al., 2011). Hence,
whereas the insulinotropic actions of GIP appear consistently
diminished in the setting of moderate hyperglycemia, GIP retains
its ability to stimulate glucagon secretion under hyperglycaemic
conditions, through incompletely understood mechanisms.
Liver
GLP-1R agonists inhibit hepatic glucose production (HGP) and
reduce hepatic lipid content; however, whether hepatocytes ex-
press the GLP-1R is controversial. Analysis of liver RNA by PCR
with primers that span the Glp1r coding region demonstrates
that murine hepatocytes do not express full-length (1.4 kb)
Glp1r mRNA transcripts (Panjwani et al., 2013), nor do theyCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 825
Figure 5. Biological Actions of GIP
The direct and indirect actions of GIP on target tissues are illustrated.
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2007). Conversely, Glp1r mRNA transcripts (453 bp product)
were detected by RT-PCR, and western blot analysis identified
a putative GLP-1R-immunoreactive protein of56 kDa with pro-
tein extracts from rat hepatocytes (Svegliati-Baroni et al., 2011).
GLP-1R expression was also reported in human liver by RT-PCR
(142 bp product) and western blotting; however, specific
GLP-1R binding sites were not detected in human liver sections
by receptor autoradiography (Ko¨rner et al., 2007). The discrepant
findings may reflect interspecies variability, and/or technical
issues related to antisera sensitivity and specificity, and detec-
tion of partial but not full-length Glp1r complementary DNAs by
PCR. Characterization of the sensitivity and specificity of three
commonly utilized GLP-1R antisera revealed that although these
antisera detect immunoreactive proteins of a size consistent with
that of the GLP-1R, similar proteins were detected in extracts
from Glp1r/ mice and none of these antisera was sufficiently
sensitive to recognize the GLP-1R by conventional or enhanced
immunoprecipitation/immunoblotting western blot analysis
(Panjwani et al., 2013). Whether human hepatocytes express
the GLP-1R also remains uncertain.
GLP-1R agonists inhibit endogenous glucose production
(EGP) in preclinical studies through mechanism(s) that remain
unclear. GLP-1 may regulate HGP indirectly through stimulation
of insulin release or via the brain through central mechanisms
(Figure 2). GLP-1 suppressed hepatic glucose production826 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.when administered into the lateral ventricle (0.01 mg/min) of
male mice during a 2 hr hyperinsulinemic-euglycemic clamp,
whereas i.c.v. infusion of Ex-9 (0.01 mg/min) blunted the GLP-
1-dependent suppression of HGP (Burmeister et al., 2012). Inhi-
bition of EGP was seen after GLP-1 administration into the
arcuate nucleus of nondiabetic rats, but GLP-1 had no effect
on EGP after injection into the third ventricle or paraventricular
nucleus (Sandoval et al., 2008). However, administration of
GLP-1 into the third ventricle enhanced insulin secretion during
an intravenous glucose tolerance test. In contrast, arcuate
GLP-1 injection had no effect on food intake, which was sup-
pressed by GLP-1 injection into the paraventricular nucleus
(Sandoval et al., 2008). Conversely, phosphorylation of Akt and
GSK-3b in the liver and suppression of hepatic glucose output
during a hyperinsulinemic-euglycemic clamp was defective in
Glp1r/ mice (Ayala et al., 2009). Thus, pharmacological and
physiological GLP-1R signaling suppresses EGP in animals in
part through actions on the central nervous system.
The GLP-1-mediated suppression of EGP in clinical studies
has been attributed to changes in glucagon and insulin levels.
However, the majority of these studies did not control for
changes in plasma insulin levels pursuant to GLP-1R activation,
or maintained circulating levels of insulin at concentrations
known to independently suppress hepatic glucose output
(150–175 pM). In contrast, GLP-1 suppressed EGP when
infused (1.2 pmol/kg/min) into nondiabetic subjects during a
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tained at concentrations that do not suppress EGP (25 pM)
(Seghieri et al., 2013), demonstrating that GLP-1 can inhibit
hepatic glucose production independent of changes in insulin
and glucagon. Although experimental conditions in this study
transiently mimicked a diabetic state (elevated plasma glucose
and glucagon:insulin ratios), whether GLP-1 also suppresses
EGP in diabetic subjects independent of changes in islet hor-
mones requires clarification.
GLP-1R agonists reduced hepatic steatosis and decreased
plasma levels of liver enzymes in high-fat-fed or genetically
obese rodents (Ding et al., 2006; Mells et al., 2012); however,
the reduction in hepatic steatosis was frequently associated
with weight loss. In contrast, treatment with the GLP-1R agonist
AC3174 (30 mg/kg/day for 4 weeks) produced reductions in liver
weights and hepatic lipid content similar to those achieved in
pair-fed mice fed a high-trans-fat diet (Trevaskis et al., 2012).
Acute central activation of GLP-1R signaling rapidly reduced
hepatic triglyceride content under hyperinsulinemic conditions
in high-fat-fed mice (Burmeister et al., 2012). However, hepatic
triglyceride secretion was reduced in the absence of peripheral
hyperinsulinemia after i.c.v. Ex-4 administration in high-fat-fed
mice (Panjwani et al., 2013). Although GLP-1R activation clearly
reduces hepatic fat, possibly via effects on hepatic lipid synthe-
sis and lipid oxidation, the precise mechanism(s) underlying
GLP-1-mediated reduction in hepatic fat remain unclear.
GLP-1R agonists also reduce hepatic steatosis in humans.
Exenatide (10 mg, twice daily) decreased ALT levels in subjects
with T2DM (both male and female, A1C = 8.2% at start of ther-
apy) in an uncontrolled, open-label study over a 3 year period
(Klonoff et al., 2008). However, 84% of the subjects lost weight,
and those that lost themost weight (12.5 kg) showed the great-
est improvement in alanine aminotransferase (ALT) levels,
whereas ALT levels did not change in the absence of weight
loss. Liraglutide (1.8 mg/day), in combination with metformin
(1.5–2 g/day) increased the liver-to-spleen attenuation ratio, a
surrogate measurement of reduced hepatic steatosis, and
reduced ALT levels in T2DM subjects over 26 weeks (Jendle
et al., 2009). However, liraglutide also caused weight loss
(3 kg) and decreased adiposity. Since GLP-1R agonists simul-
taneously reduce hepatic steatosis and body weight, it is difficult
to attribute reduced hepatic steatosis to actions of GLP-1R
agonists independent of weight loss. However, exenatide
(10 mg twice daily) plus pioglitazone (45mg/day) reduced hepatic
triglyceride content, decreased circulating levels of liver en-
zymes, and increased adiponectin levels in T2DM patients
without changes in body weight over a 12 month period (Sathya-
narayana et al., 2011). Hence, it remains possible that GLP-1R
activation regulates hepatic lipid synthesis, secretion, uptake,
or oxidation, resulting in reduction of hepatic fat content inde-
pendent of changes in body weight. Ongoing clinical trials are
assessing the potential benefits of GLP-1R agonists in over-
weight human subjects with or without diabeteswith pre-existing
steatohepatitis.
Adipose Tissue
GLP-1 and White Adipose Tissue. GLP-1 actions have been
studied in differentiated 3T3-L1 cells; however, whether GLP-
1R expression is localized to adipocytes in vivo is unclear.
GLP-1 binding sites were detected in solubilized membranesfrom both human and rat white adipose tissue (WAT) using radio-
ligand binding assays, whereas others have been unable to
detect Glp1rmRNA transcripts in human or rat WAT. Full-length
Glp1r transcripts (1.4 kb) were detected in RNA from the stromal
vascular fraction (SVF) of murine adipose tissue (Panjwani et al.,
2013), and RT-PCR and immunohistochemistry detected GLP-
1R expression in adipocytes and the SVF of human visceral
adipose tissue from obese male and female subjects (Vendrell
et al., 2011). However, the specificity of the GLP-1R antisera
employed in these studies remains uncertain (Panjwani et al.,
2013). Although central GLP-1R activation may indirectly in-
crease brown adipose tissue (BAT) thermogenesis in rodents
(see below), Glp1r expression has not been reported in adult
murine BAT.
GLP-1 (10–100 nM, 4 hr) increased lipolytic rates in human pri-
mary adipocytes in vitro (Vendrell et al., 2011). However, GLP-1
infusion (1 mM, 80 min) into abdominal subcutaneous adipose
tissue via in situ microdialysis failed to demonstrate a lipolytic
effect in healthy human volunteers (Bertin et al., 2001). i.c.v.
GLP-1 infusion (0.75 nmol/day for 7 days) decreased adiposity,
whereas, i.c.v. infusion of Ex-9 (7.5 nmol/day for 7 days)
increased fat mass in 8- to 10-week-old male mice (Nogueiras
et al., 2009). Although central infusion of GLP-1 increased
peripheral levels of total GLP-1, indicating leakage into the
periphery, subcutaneous infusion of identical concentrations of
GLP-1 (0.75 nmol/day) did not recapitulate the effects seen
with central administration. The ability of central GLP-1R activa-
tion to reduce WAT mass was independent of changes in food
intake and mediated through increased sympathetic outflow.
Additionally, i.c.v. but not peripheral administration of GLP-1
decreased lipogenic gene expression (Fas, Scd-1, and Acca)
and significantly reduced triglyceride content in WAT after
2 days (Nogueiras et al., 2009). In contrast, i.c.v. GLP-1 did not
decrease body weight or alter lipogenic gene expression in
WAT of triple beta-adrenoreceptor knockout mice, a murine
model lacking a functional sympathetic nervous system. i.c.v.
GLP-1 (0.75 nmol/day for 2 days) administered to high-fat-fed
obese, wild-type mice failed to alter body mass or lipogenic
gene expression in WAT, suggesting an obesity-induced resis-
tance to CNS GLP-1 communicating with WAT. The available
data indicate that the actions of GLP-1 on adipose tissue are pre-
dominantly indirect and modulated through increased sympa-
thetic tone (Figure 2), leading to decreased lipogenesis and
reduced triglyceride content. Whether one or more WAT depots
express a functional GLP-1R in human subjects requires further
experimentation.
GLP-1 and Brown Adipose Tissue. GLP-1 communicates with
rodent BAT through the CNS to increase thermogenesis
(Figure 2). Acute i.c.v. injection of GLP-1 (1 nmol) increased intra-
scapular BAT temperature in 12- to 14-week-old male mice,
whereas peripheral GLP-1 administration had no thermogenic
effect (Lockie et al., 2012). CNS administration of GLP-1
increased sympathetic nerve activity toward intrascapular BAT.
Additionally, i.c.v. injection of oxyntomodulin (1 nM), a progluca-
gon-derived peptide with mixed Gcgr/GLP-1R activity,
mimicked the effects of GLP-1 on BAT sympathetic nervous sys-
tem activity and increased expression of Pgc-1a and Ucp1 in
BAT from wild-type, but not Glp1r/, mice. Nevertheless,
Glp1r/ mice did not exhibit basal abnormalities in BATCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 827
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and compelling evidence that GLP-1R agonists increase energy
expenditure in diabetic or obese human subjects is lacking.
Hence, while central pharmacological GLP-1R activation in-
creases BAT thermogenesis in rodents, the endogenous GLP-
1R is not required for the thermogenic adaptive physiological
response to cold. Furthermore, there is no compelling evidence
that GLP-1R agonists increase thermogenesis in human
subjects.
GIP and White Adipose Tissue. Activation of the rodent GIPR
increases the uptake of lipids, enhances adipokine secretion,
and promotes weight gain, expansion of adipose tissue depots,
and insulin resistance (Figure 5) (Lamont and Drucker, 2008),
whereas Gipr/ mice are protected from high-fat-feeding-
induced obesity (Miyawaki et al., 2002). Similarly, activation of
GIPR expression in rodent or human adipocytes ex vivo induces
cytokine and osteopontin expression and impairs insulin-sensi-
tive glucose uptake ex vivo, and GIP levels correlate with body
mass index (BMI) and impaired insulin sensitivity in human sub-
jects (Ahlqvist et al., 2013). Attenuation of GIP action with immu-
noneutralizing antisera, or elimination of GIP-producing K cells,
also produces resistance to diet-induced obesity in preclinical
studies. Ablation of enteroendocrine K cells markedly impairs
the incretin effect to a greater extent than in Gipr/ mice, find-
ings potentially explained by the importance of GIP as an endo-
crine factor stimulating GLP-1 secretion and by deficiency of
xenin-25, which acts as a cofactor for GIP action on the b cell
(Althage et al., 2008; Wice et al., 2010). Transgenic rescue of
GIPR expression in adipocytes of Gipr/ mice restores the
weight gain response to high-fat feeding; surprisingly, however,
the increase in body mass was attributed to expansion of lean
body mass with no effect on the adipose tissue compartment
(Ugleholdt et al., 2011). Although GIP in the absence of insulin
has little consistent impact on adipocyte lipid metabolism, free
fatty acids, or triglycerides in human subjects, the combination
of GIP plus insulin had a greater effect to increase adipose tissue
blood flow in lean nondiabetic human subjects than did infusion
of insulin or GIP alone (Asmar et al., 2010). In contrast, infusion of
GIP alone (2 pmol/kg/min) increased insulin levels, lowered
circulating levels of free fatty acids after 60 min, and decreased
expression of 11b-HSD1 and adipose triglyceride lipase in adi-
pose tissue without changes in triglyceride levels in healthy
male nondiabetic subjects (Go¨gebakan et al., 2012). Human
subjects with the Gipr SNP (rs10423928) have reduced BMI
and lean body mass and waist circumference, consistent with
a reduction in adipogenesis (Lyssenko et al., 2011). Whether
this phenotype reflects decreased GIPR signaling in adipose tis-
sue, reduced circulating insulin levels, or interactions between
the b cell and adipose tissue is unclear. Additional evidence for
potential complexity of GIPR signaling in human adipocytes is
reflected by the detection of 64 splice variants of the Gipr via
RT-PCR analysis of RNA from human abdominal subcutaneous
tissue (Ahlqvist et al., 2013); only two of the 64 transcripts were
predicted to encode a full-length GIPR protein. Hence, potential
heterogeneity of GIP action in human adipose tissue may be
accounted for in part by genetic variation in the Gipr.
Nonmetabolic Actions of Incretins in the Brain
GLP-1.GLP-1 is produced within the CNS and peripheral GLP-1
produced by the L cell (1) crosses the blood-brain barrier and (2)828 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.communicates with the brain via sensory afferent vagal neurons.
The relative importance of these signaling pathways is difficult to
ascertain. GLP-1 receptors are expressed throughout the brain,
in regions that control glucose homeostasis, gut motility, food
intake, aversive signaling, and cardiovascular function. As
outlined below, GLP-1R signaling exerts neuroprotective and
neurotrophic effects, with implications for the treatment of
neurodegenerative diseases.
Alzheimer’s disease is characterized by deposits of amyloid b
protein (Ab) and the microtubule-associated protein Tau, result-
ing in senile plaques, neurofibrillary tangles, and progressive
dementia. An acute bolus of Ab i.c.v. (10–100 nmol) diminished
long-term potentiation (LTP) induced by high-frequency stimula-
tion, whereas a GLP-1R agonist (15 nmol, i.c.v.) prevented the
Ab-induced reduction of LTP in male rats (Gault and Ho¨lscher,
2008a). Infusion of GLP-1 or Ex-4 (3.3–6.6 ng or 0.2 ng, respec-
tively) into the lateral ventricles of lean male mice reduced
endogenous levels of Ab and treatment of rat primary hippocam-
pal cultures (GLP-1, 5–20 nM; Ex-4, 100–500 nM; 24 hr)
prevented neuronal death induced by Ab (Perry et al., 2003).
Exogenous Ab also activates the JNK/TNF-a pathway, leading
to impaired insulin action in hippocampal neurons cultured
ex vivo; Ex-4 (25 nmol/kg/day, 3 weeks, intraperitoneal [i.p.])
prevented Ab-induced JNK activation and decreased serine
phosphorylation in hippocampal neurons frommale amyloid pre-
cursor protein (APP)/PS1 transgenic mice, leading to improved
brain insulin signaling, spatial memory, and memory retention
(Bomfim et al., 2012). Conversely, Glp1r/ mice demonstrated
impaired synaptic plasticity and memory formation and blunted
LTP in the hippocampus after pulse stimulation (Abbas et al.,
2009). Consistent with the importance of the endogenous
GLP-1R for control of memory and neuronal integrity, rescue of
hippocampal GLP-1R expression with a recombinant adeno-
associated virus ameliorated the learning deficit and decreased
kainic acid-induced neurotoxicity in Glp1r/mice (During et al.,
2003). A randomized, double-blind clinical trial examining the
effects of daily liraglutide (1.8 mg/day) on intracerebral amyloid
deposits in the CNS of patients with Alzheimer’s disease is
ongoing.
Parkinson’s disease is characterized by loss of dopaminergic
signaling in nigrostriatal neurons, which also express the GLP-
1R. GLP-1 or Ex-4 (0.1 mM) maintained cell viability during hyp-
oxic injury in primary neuronal cultures isolated from rat cerebral
cortical cells; these actions were prevented by Ex-9 (10 mM) and
absent in neurons from Glp1r/ mice (Li et al., 2009). Similarly,
pretreatment with GLP-1 or Ex-4 (0.1 mM) reduced apoptosis
and preserved survival of rat primary ventral mesencephalic cells
exposed to dopaminergic toxin 6-hydroxydopamine (6-OHDA)
(Li et al., 2009). The protective effects of GLP-1 were abolished
by inhibitors of PKA or PI3K. Continuous Ex-4 administration
(20 nM, 0.25 ml/hr, i.c.v.) for 7 days prevented neuronal death,
maintained levels of brain dopamine, and preserved motor func-
tion in mice exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP), a chemically induced model of Parkinson’s
disease. Acute treatment with Ex-4 (43 10 mg/kg, i.p.) prevented
MPTP-induced microglial activation, decreased mRNA levels
of TNF-a and IL-1b in the ventral midbrain, and preserved
neuronal density in 8-week-old male C57BL/6 mice (Kim et al.,
2009). Similarly, Ex-4 (0.5 mg/kg/day) given 7 days after i.c.v.
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nergic neurons, restored dopamine levels, and improved behav-
ioral test scores in rats.
Amyotrophic lateral sclerosis (ALS) is characterized by pro-
gressive degeneration of motor neurons in the CNS. Ex-4
(100 nM) improved cell viability and reduced apoptosis after
hydrogen peroxide-induced oxidative stress in NSC19 neuronal
cells, a cell line that resembles spinal cord cells (Li et al., 2012).
Administration of Ex-4 (3.5 pmol/kg/min, subcutaneous [s.c.]) for
12 weeks preserved spinal cord structure, reduced caspase-3-
positive neurons in the lumbar spine, and maintained motor
neuron density and function in SOD1 G93A mice, a genetic
model of ALS (Li et al., 2012).
GLP-1R activation reduces cell death after ischemic injury in
the brain. Ex-4 (21 ng, i.c.v.) given 15min prior to middle cerebral
artery occlusion (MCAO) reduced infarct size in wild-type but not
in Glp1r/ mice (Li et al., 2009). Intravenous administration of
Ex-4 (10 mg) after middle cerebral artery injury reduced oxidative
stress, inflammation, and the number of apoptotic cells in the
ischemic boundary zone in 8-week-old male mice (Teramoto
et al., 2011). However, whether GLP-1 elicits direct neuroprotec-
tive/neuroregenerative effects or acts in the brain through indi-
rect mechanisms is unclear. Infusion of GLP-1 (1.2 pmol/kg/
min) increased glucose clearance in the brain, reduced intrace-
rebral glucose concentrations, and enhanced flow across the
blood-brain barrier in a randomized, double-blind, placebo-
controlled crossover study in nine healthy men undergoing a
pancreatic clamp (Gejl et al., 2012). The enhanced cerebral
clearance of glucose suggests blood flow to the brain was
increased; however, cerebral blood flow was not directly
measured. The potential for GLP-1 to elicit neuroprotective
effects indirectly through alterations in cerebral blood flow
or reductions in brain hyperglycemia requires additional
investigation.
GIP. Gipr mRNA and protein are expressed in the hippocam-
pus, cerebral cortex, and olfactory bulb in rats and in the hippo-
campus and neocortex of human subjects (Figueiredo et al.,
2011). GIP-producing cells have been identified throughout the
rat brain, with relatively higher mRNA and protein expression in
the olfactory bulb, hippocampus, hypothalamus, thalamus, and
cerebellum (Nyberg et al., 2007). Whether GIP crosses the
blood-brain barrier in physiologically relevant concentrations is
not clear; hence, the relative importance of central versus
peripheral-derived GIP remains uncertain.
Exogenous administration of GIP (1.92 nmol/day for 5 days,
i.c.v.) increased proliferation of hippocampal rat progenitor cells,
whereas Gipr/ mice demonstrated a reduction in proliferating
cells in the hippocampal dentate gyrus (Nyberg et al., 2005). GIP
also increased the proliferation of rat adult hippocampal progen-
itor (AHP) cells in a dose-dependent manner, actions prevented
by antagonism of the GIPR. Acute GIP administration (15 nmol,
i.c.v.) prevented the detrimental effects of Ab on long-term
potentiation in rats, consistent with actions of GIP to improve
synaptic plasticity in the hippocampus (Gault and Ho¨lscher,
2008b). Chronically, [D-ALA2]GIP (25 nmol/kg twice daily for
28 days, s.c.) prevented the decrease in LTP induced by high-
fat feeding in rats and improved object recognition memory.
Treatment with [D-ALA2]GIP (25 nmol/kg/day for 35 days, i.p.)
reduced Ab deposits in the cortex and reduced oxidative stressand inflammation in both the cortex and hippocampus of 12- to
19-month-old APP/PSI transgenic mice (Duffy and Ho¨lscher,
2013). Conversely, Gipr/ mice have impaired recognition and
spatial learning and reduced LTP in the hippocampus (Faivre
et al., 2011). It still remains to be determined whether and how
peripheral administration of GIPR agonists communicates with
the brain. There are no data examining the potential conse-
quences of modulating brain GIP receptor activity in humans.
Gipr mRNA transcripts have been localized to cells within the
hypothalamus, pituitary, and adrenal cortex, andGIPR activation
increases plasma corticosterone in rodents (Bates et al., 2012).
Conversely, Gipr/ mice exhibit reduced meal-related in-
creases in plasma corticosterone, raising the possibility that
alterations in glucocorticoid tone in rodents contribute to
changes in adiposity after enhanced or reduced GIPR signaling.
Nevertheless, glucocorticoid replacement at physiological levels
did not reverse the metabolic phenotypes ofGipr/mice (Bates
et al., 2012). Although ectopicGIPR expression in human adrenal
tumors underlies the pathophysiology of food-induced Cush-
ing’s syndrome in some patients, the importance of a GIPR-
hypothalamic-pituitary-adrenal axis for human glucocorticoid
secretion has not been established.
Immune System
Full-length (1.4 kb) Glp1r mRNA transcripts were identified in
multiple immune cell subpopulations from C57Bl/6 and NOD
mice, including thymoyctes, splenocytes, bone-marrow-derived
cells, and regulatory T cells (Hadjiyanni et al., 2010). Further-
more, GLP-1R agonists increased lymphocyte cAMP formation
in a GLP-1R- and Ex-9-dependent manner. Nomajor differences
in the number or localization, cell survival, or chemotaxis of
different immune subpopulations were detected in lymphocytes
from peripheral lymph nodes, spleen, or thymus of Glp1r/
mice; however, Glp1r/ lymphocyte subpopulations exhibited
modest impairments in the proliferative response to mitogenic
stimuli (Hadjiyanni et al., 2010). Although Glp1r expression has
been reported in human macrophages and macrophage cell
lines, murine macrophages (C57BL/6, ApoE/, and IL-10/)
reflecting various activity states (M1 and M2 polarized) do not
express full-length Glp1r mRNA transcripts (Panjwani et al.,
2013). Invariant natural killer T (iNKT) cells, innate immune cells
implicated in the pathogenesis of psoriasis, express Glp1r
mRNA transcripts, and liraglutide (15 mg/ml) increased levels of
cAMP and CREB phosphorylation and regulated cytokine pro-
duction in iNKT cells (Hogan et al., 2011).
The anti-inflammatory actions of GLP-1R agonists in the CNS
include suppression of proinflammatory cytokines and reduced
microglial activation. Similar anti-inflammatory properties of
GLP-1 have been reported in the pancreas and cardiovascular
system. Ex-4 (100 nM, 6 hr), combined with the phosphodies-
terase inhibitor rolipram (15 mM), suppressed the mRNA and
protein levels and secretion of the proinflammatory cytokine
CXCL10 in human islets treated with interferon g (IFN-g) (Pugaz-
henthi et al., 2010). The anti-inflammatory effects of Ex-4 in islets
were mediated through increased cAMP and were prevented by
inhibition of adenylyl cylase (Sq22536, 100 mM), whereas forsko-
lin (20 mM) and dibutyryl-cAMP (1 mM) reproduced the actions of
Ex-4. Administration of Ex-4 (24 nM, twice daily, i.p.) for 4 weeks
reduced levels of mRNA transcripts for proinflammatory cyto-
kines (Mcp-1, Tnfa, and Stat3) in the pancreas of high-fat-fedCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 829
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1R activity had no effect on the severity of caerulein-induced
pancreatitis. Liraglutide (30 nM, 2.5 hr) attenuated apoptosis
and decreased TNF-a-induced ROS production, PKC activation,
and NF-kB activation in primary human endothelial cells (Shiraki
et al., 2012). Liraglutide (10–100 nM) also reduced TNF-a
(100 ng/ml, 24 hr)-induced caspase-3 activation in murine cardi-
omyocytes, actions abolished by Ex-9 (10 mM) (Noyan-Ashraf
et al., 2009). Hence, GLP-1R activation reduces inflammation
and promotes cell survival in multiple organs and cell types.
GLP-1R agonists ameliorate the severity of type 1 diabetes in
mice, inducing disease remission in association with enhanced
numbers of regulatory T cells. Continuous administration of
GLP-1 for 4 or 8 weeks delayed or prevented the development
of diabetes and insulitis, with increased b cell proliferation and
reduced apoptosis being detected in GLP-1-infused mice
(Zhang et al., 2007). Ex-4 (0.1–4 mg/day) delayed the onset of
diabetes and reduced lymphocyte infiltration into the islets of
female NOD mice when Ex-4 administration was started at 4 or
9 weeks of age (Hadjiyanni et al., 2008). Furthermore, GLP-1
(10-100 mg/kg/day for 3 weeks) plus gastrin (1.5 mg/kg) restored
normoglycemia and increased islet insulin content and b cell
mass in diabetic, female NOD mice; however, neither GLP-1
nor gastrin alone were effective (Suarez-Pinzon et al., 2008).
GLP-1/gastrin treatment increased the number of TGF-b1-
secreting lymphocytes and decreased INF-g-secreting lympho-
cytes within islets transplanted into diabetic, female NOD mice.
The transplanted islets demonstrated improved survival and
decreased apoptosis after GLP-1/gastrin administration, result-
ing in the delayed onset of diabetes (Suarez-Pinzon et al., 2008).
Thus, GLP-1R activation modulates lymphocyte activation
to favor an anti-inflammatory phenotype that promotes islet
function.
Clinically, 4 weeks of liraglutide treatment (1.2 mg/day)
decreased the daily insulin dose and HbA1c levels in both
C-peptide-positive and -negative subjects with T1DM (Kielgast
et al., 2011). Liraglutide did not alter basal or glucagon-stimu-
lated C-peptide levels (duration of diabetes = 3.7 years) but did
reduce the amount of time spent in hypoglycaemia (<3.9 mM),
and two liraglutide-treated C-peptide-positive subjects discon-
tinued insulin therapy. The reduction in insulin dose achieved
was proportional to the baseline C-peptide status prior to initia-
tion of therapy (Kielgast et al., 2011). In contrast, treatment of
subjects with long-standing (20+ years), C-peptide-positive
T1DMwith exenatide (at doses up to 40 mg daily) and insulin ther-
apy with or without daclizumab in a crossover design did not
result in augmentation of insulin secretion, despite the consider-
able weight loss (mean 4.2 kg) achieved on exenatide (Rother
et al., 2009). Thus, more-extensive studies are warranted
to investigate whether GLP-1R activation improves glucose
homeostasis independent of glucagon secretion and gastric
emptying and to determine whether therapy with GLP-1R ago-
nists can improve or maintain b cell function in newly diagnosed
patients with T1DM.
The finding that GLP-1R agonists modulate iNKT cell activity
prompted assessment of the role of GLP-1R agonists in diseases
such as psoriasis. GLP-1 treatment (150 mg/ml, 24 hr) of iNKT
cells increased the production of IFN-g and IL-4 under resting
conditions but inhibited the production of these cytokines in acti-830 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.vated iNKT cells in an Ex-9-dependent manner. Liraglutide
reduced the Psoriasis Area and Severity Index (PASI) score,
decreased the number of iNKT cells in the psoriatic plaque,
and increased the number of circulating iNKT cells in two obese
patients with T2DM (Hogan et al., 2011). Although these im-
provements ensued without major changes in glycemia, both
subjects lost weight (5 kg), and weight loss may independently
improve psoriasis. Similarly, liraglutide (1.2 mg/day, 10 weeks)
decreased the PASI score and reduced body weight in a pro-
spective, open-label, cohort study of seven subjects with
T2DM and psoriasis (Ahern et al., 2012). Whether GLP-1R ago-
nists reduce psoriasis disease activity independent of weight
loss is an important question that should be answered in ongoing
studies.
Kidney
Glp1r mRNA transcripts are expressed in the kidney; however,
the cellular localization of GLP-1R expression in renal blood ves-
sels, glomerular cells, or tubular cells requires more-precise
confirmation. The kidney plays an important role in the degrada-
tion of native GLP-1 and in the clearance of some peptide-based
degradation-resistant GLP-1R analogs. GLP-1 infusion pro-
motes a rapid natriuretic and diuretic response in multiple spe-
cies, including normal and obese insulin-resistant human
subjects (Gutzwiller et al., 2004) through incompletely under-
stoodmechanisms that may involve neural signals, indirect regu-
lation of vasoactive hormones such as atrial natriuretic factor
(Kim et al., 2013), or direct actions on renal tubular cells and
sodium transporters. Experiments using kidney cell lines and
rodent kidney preparations implicate a direct role for GLP-1R
agonists in the control of tubular sodium excretion through regu-
lation of Na(+)/H(+) exchanger isoform 3 (NHE3) via mechanisms
sensitive to PKA inhibition (Crajoinas et al., 2011). Although both
DPP-4 inhibitors and GLP-1R agonists rapidly promote urine
sodium excretion, DPP-4 inhibitors enhance urine sodium excre-
tion even in Glp1r/ mice (Rieg et al., 2012). Administration of
GLP-1R agonists reduces proteinuria and produces functional
and histological improvement in the diabetic kidney in preclinical
studies of diabetic nephropathy in rodents. Kodera and col-
leagues administered Ex-4 (10 mg/kg daily for 8 weeks) to rats
with streptozotocin-induced diabetes and detected consider-
able improvement in renal function, decreased proteinuria, and
reduced inflammation and fibrosis in the kidney, independent
of changes in blood glucose or body weight (Kodera et al.,
2011). However, the majority of studies examining GLP-1 action
in preclinical models of kidney disease do not control for poten-
tial indirect benefits ensuing from changes in blood glucose,
insulin levels, or weight loss. To date, there is little compelling
evidence from randomized controlled trials that GLP-1R
agonists attenuate the development of renal disease in human
subjects.
GLP-1 and Bariatric Surgery
Improvements in blood glucose and reduction in body weight
after bariatric surgery are often correlated with increases in
circulating levels of gut hormones such as GLP-1. Although
some patients treated with GLP-1R agonists achieve substantial
weight loss and marked improvements in diabetic control, these
patients are rare, and in themajority of studies, only 50%–60%of
patients achieve a HbA1c close to 7%, with a mean weight loss
of 2–4 kg. Even in nondiabetic obese subjects treatedwith higher
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Reviewdoses of liraglutide (3 mg daily), the weight loss achieved is
considerably less than that observed after gastric bypass sur-
gery (GBS) (Astrup et al., 2009). Furthermore, the observation
that clinical trials employing low calorie diets also produce major
improvements in diabetes and considerable weight loss without
changes in circulating GLP-1 further challenges the notion that
increased levels of GLP-1 play an essential role in the ameliora-
tion of diabetes and obesity observed after bariatric surgery.
Bradley and colleagues assessed the metabolic consequences
of laparascopic adjustable gastric banding, a condition not asso-
ciated with increased plasma levels of gut hormones, with the
Roux-en YGBS, in nondiabetic obese subjects after comparable
amounts (20%) of weight loss. The improvement in b cell func-
tion and insulin resistance was primarily attributed to weight loss
in both groups (Bradley et al., 2012), independent of the multiple
different features of the two bariatric surgery procedures. The
importance of GLP-1 action for metabolic improvements after
bariatric surgery has been examined with murine models,
including vertical sleeve gastrectomy (VSG). Although circulating
levels of GLP-1 were significantly elevated in mice after VSG,
food intake, weight loss, macronutrient selection, and improve-
ments in b cell function and glucose homeostasis were similar
after VSG in two different models of whole body inactivation of
the Glp1r (Wilson-Pe´rez et al., 2013).
A subset of patients experience persistent severe recurrent
hypoglycemia after bariatric surgery, eventually requiring subto-
tal or total pancreatectomy for symptom management; many of
these patients have very high levels of GLP-1 after meal inges-
tion. In some patients, attenuation of the hypoglycemia may be
achieved by prescription of small meals with low-carbohydrate
composition or by suppression of rapid gut motility and GLP-1
secretion with somatostatin analogs. Although pancreata from
some hyperinsulinemic hypoglycemic subjects exhibit enlarged
islets and histological evidence of nesidioblastosis, these find-
ings were not associated with enhanced GLP-1R expression in
islets from affected individuals (Reubi et al., 2010). Subjects
with recurrent hypoglycemia and hyperinsulinemia after meal
ingestion after GBS often exhibit much higher levels of GLP-1;
however, studies using Ex-9 to block GLP-1 action in GBS sub-
jects did not reveal major differences in the contribution of GLP-1
to enhanced insulin secretion in patients with or without symp-
tomatic hypoglycemia (Salehi et al., 2011). Hence, although
very high GLP-1 responses after GBS promote hyperinsulinemia
and hypoglycemia, additional factors beyond GLP-1 likely
contribute to sensitization of b cell function and exaggerated
insulin release in many subjects after GBS.
GLP-1, the Exocrine Pancreas, and Pancreatitis
Whether activation of GLP-1R signaling increases the risk of
pancreatitis remains uncertain. Ex-4 (10 mg/kg/day for 75 days)
modestly increased plasma lipase activity, an indirect reflection
of pancreatitis, and enhanced focal histological inflammation in
the pancreas of male, Sprague-Dawley rats (Nachnani et al.,
2010). However, the animals lost significant amounts (30%) of
body weight, an independent risk factor for pancreatitis. Several
studies have failed to detect biochemical or histological evi-
dence of pancreatitis in mice or rats continuously treated with
GLP-1R agonists for several months. Administration of Ex-4
(0.072–0.72 nmol/kg) for 4 weeks did not alter plasma amylase
or lipase activity in rats, and acute Ex-4 administration (0.072–0.72 nmol/kg, 6 hr) decreased the activity of both enzymes after
chemically induced pancreatitis (caerulein, 10 mg/kg) in male
Sprague-Dawley rats (Tatarkiewicz et al., 2010). Similarly, Ex-4
(7.2 nmol/kg/day for 4 weeks) attenuated increases in plasma
amylase and lipase activity after induction of acute pancreatitis
(caerulein, 5 3 10 mg/kg) in ob/ob mice and reduced acute
inflammation and vacuolation in the exocrine pancreas (Tatarkie-
wicz et al., 2010). Liraglutide (75 mg/kg/day for 7 days) enhanced
the expression of anti-inflammatory genes (REGIIIa and REGIIIb)
in wild-type but not in Glp1r/ mice (Koehler et al., 2009),
whereas Ex-4 administered prior to or after the administration
of caerulein (6 mg/kg) did not modify the severity of or recovery
from pancreatitis. Thus, acute or sustained GLP-1R signaling
does not promote enhanced susceptibility to pancreatitis.
Clinically, exenatide therapy did not increase the relative risk
of pancreatitis compared with other antidiabetic agents in retro-
spective analyses of large health care claims databases (Dore
et al., 2009; Garg et al., 2010). Nevertheless, acute exenatide
administration inhibited cholecystokinin-stimulated gall bladder
emptying in healthy nondiabetic subjects (Keller et al., 2012),
and multiple isolated cases associating GLP-1R agonists with
the development of acute pancreatitis have been reported.
Furthermore, pancreatic enzyme levels may be increased in a
subset of asymptomatic patients treated with GLP-1R agonists;
hence, the actions of GLP-1R agonists on the function of the
exocrine pancreas and biliary tract in diabetic or obese human
subjects requires further study.
Incretin Action in the Skeleton. There is little evidence that
GLP-1R agonists directly modify bone formation or resorption.
In rodents, the GLP-1R is expressed on calcitonin-producing C
cells, and GLP-1R activation rapidly increases calcitonin secre-
tion in rats and mice (Bjerre Knudsen et al., 2010). Conversely,
Glp1r/ mice exhibit reduced levels of calcitonin mRNA tran-
scripts in the thyroid, increased osteoclast activity, osteopenia,
and increased bone resorption, findings reversed by calcitonin
administration (Yamada et al., 2008). Although sustained GLP-
1R activation produces favorable changes in markers of bone
formation and resorption in clinical studies, there is no evidence
that GLP-1R agonists produce changes in bone strength or bone
quality in human subjects. GIP receptors have been detected in
osteoblasts, and sustained activation of GIPR expression pro-
duces anabolic actions on bone mass in rodents. Conversely,
Gipr/mice exhibit reduced osteoclast number, whereas exog-
enous GIP reduces osteoblast apoptosis in mice (Tsukiyama
et al., 2006). Although bone resorption is reduced after meal
ingestion in rodents and humans, acute GLP-1 or GIP adminis-
tration had no effect on markers of bone turnover in postmeno-
pausal women (Henriksen et al., 2003).
Future of GIP and GLP-1 Research
The therapeutic potential of manipulating GIP receptor signaling
for the treatment of diabetes or obesity remains uncertain. GIPR
agonists exhibit potent insulinotropic properties in preclinical
studies, and human genome-wide association study data corre-
late loss-of-function SNPs in the Gipr gene with oral glucose
intolerance. However, genetic or pharmacological inhibition of
GIPR signaling in preclinical studies prevents or attenuates
diet-induced obesity, and the same Gipr SNPs are associated
with reduced BMI and waist circumference in human geneticCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 831
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Reviewstudies. Future experiments should address (1) mechanism(s)
that regulate GIPR signaling in the diabetic islet resulting in
enhanced glucagon and reduced insulin secretion and (2) the
relative importance of GIPR signaling in the b cell versus the
adipocyte for adipogenesis. Themechanisms and tissues impor-
tant for GIPR-dependent control of body weight (b cell versus
adipose tissue versus CNS) also require further clarification, as
does the complexity of Gipr mRNA splicing and the expression
of GIPR isoforms in different tissues (Ahlqvist et al., 2013). The
comparative activity of GIP-GLP-1 coagonists, which exhibit
promising efficacy in preclinical studies (Tscho¨p and DiMarchi,
2012), awaits careful assessment in human clinical trials.
Although GLP-1 receptors are widely distributed in diverse ex-
trapancreatic tissues and GLP-1R agonists produce favorable
pleiotropic effects on many cells and tissues in preclinical
studies, the majority of experiments in vivo do not employ active
comparators that provide the same degree of glucose control or
weight loss. Hence, the extent to which actions attributed to
GLP-1 are direct, or indirect, arising secondary to changes in
body weight, glucose, or insulin action, requires more careful
elucidation. Furthermore, the majority of ‘‘gain-of-function’’
studies with GLP-1 (and GIP) in rodents and humans achieve
circulating levels of these peptides generally far greater than
what might be observed even during the postprandial state,
requiring consideration of the pharmacological versus the phys-
iological context of the observed action. Similarly, pharmacolog-
ical levels of GLP-1 and GIP frequently increase insulin levels in
acute and chronic preclinical studies, and few experiments
employ insulin as an active comparator for analysis of incretin
action in vivo.
Of comparable concern is the quality of the current reagents
used in studies of incretin action. Ex-9 and most GIPR antago-
nists are in fact nonselective and function as partial agonists at
their respective receptors (Tscho¨p and DiMarchi, 2012). The
majority of available incretin receptor agonists and antagonists
do not effectively or selectively penetrate the CNS, rendering
uncertain the extent to which CNS incretin action observed after
i.c.v. or intracerebral peptide administration may be extrapo-
lated to human biology. Moreover, many studies employing
i.c.v. or intracerebral peptide administration fail to assess the
extent to which these peptides leak into the systemic circulation.
The majority of antisera used to localize mouse and human GLP-
1R expression do not in fact recognize the GLP-1R under
commonly utilized experimental conditions (Panjwani et al.,
2013; Pyke and Knudsen, 2013). These findings mandate a
reevaluation of the mechanisms of GLP-1 action in different
experimental paradigms as the literature contains dozens of
publications using nonspecific antisera to infer GLP-1R expres-
sion in many tissues and cell types. Hence, the field requires
development of better reagents and much more careful charac-
terization of antisera employed for receptor localization studies.
Ongoing studies employing highly selective incretin antagonists
and cell- and tissue-specific inactivation of incretin receptor
expression should advance our understanding of how GLP-1
and GIP exert their actions in different cell types.
The effective translation of preclinical data into comparable
robust human observations is hampered by the predominant
use of young mice and rats in short term preclinical studies. It
is now widely recognized that young, healthy animals frequently832 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.exhibit profound differences in biological responses in the
endocrine pancreas, bone marrow, and immune and cardiovas-
cular systems relative to older subjects with advanced diabetes
and atherosclerosis. The considerable body of preclinical data
demonstrating induction of insulin gene expression, enhance-
ment of b cell proliferation, reduction of b cell apoptosis, and
expansion of b cell mass in young rodents (Drucker, 2003,
2006) has not been matched by robust data from carefully
controlled clinical trials attempting to demonstrate preferential
preservation of b cell function in human subjects (Drucker,
2011). Hence, more studies of incretin action in older animals
with established diabetes, obesity, and cardiovascular disease
seem warranted. The increasing use and success of incretin-
based therapies to treat T2DM and reduce body weight is
based on a robust body of scientific observations, spanning
cellular and molecular biology, preclinical animal studies, and
human clinical trials. Future advances in our understanding of
incretin biology, and development of coagonists employing
two or more incretin-related peptide epitopes within a single
molecule (Day et al., 2009; Pocai et al., 2009), may expand
the domain of incretin-based therapies into new therapeutic
areas and have important implications for the safe and effective
use of current incretin-based agents for the treatment of human
disease.
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